The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

NCT06984159 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Prostate Cancer

Interventions

DRUG: Leuprolide Injectable Emulsion (CAMCEVI®)

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.